Type 2 Diabetes & ASCVD: Cardiovascular Risk Reduction According to the Guidelines

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Type 2 Diabetes & ASCVD: Cardiovascular Risk Reduction According to the Guidelines

Program Information

Program Information

ReachMD Healthcare Image

Explore the latest guideline recommendations for managing patients with type 2 diabetes and atherosclerotic cardiovascular disease.

  • Sponsored by

  • Overview

    Atherosclerotic cardiovascular disease (ASCVD) is the number one cause of death and disability in patients with type 2 diabetes.1 So what do the latest guidelines from the ADA, ACC, and AHA recommend for managing patients with both type 2 diabetes and ASCVD? Find out with Dr. Matthew Budoff, Professor of Medicine at the David Geffen School of Medicine at UCLA in Los Angeles, as he reviews the latest guideline recommendations for comprehensive cardiovascular risk reduction.

    1. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459-2502.

    Novo Nordisk is a registered trademark of Novo Nordisk A/S.
    © 2022 Novo Nordisk All rights reserved.
    US22DI00249 August 2022

Schedule7 Dec 2022